CPC Scientific to Showcase Peptide and Oligonucleotide CDMO Leadership at CPHI Frankfurt 2025
October 1, 2025
Rocklin, CA – CPC Scientific Inc., a global Contract Development and Manufacturing Organization (CDMO) specializing in peptides and oligonucleotides, and a subsidiary of Medtide Inc., will have a major presence at CPHI Frankfurt 2025, taking place October 28–30 at Messe Frankfurt, Germany.
As its flagship annual event, CPC Scientific will spotlight its leadership in the rapidly expanding peptide and oligonucleotide sector and its strategic role as a trusted global partner.
Driving Innovation in Peptides and Oligonucleotides
CPC Scientific is well-positioned to capture emerging opportunities in the growing global TIDES drug market, especially in the dynamic GLP-1 therapeutic space. Visitors can connect with CPC Scientific at Booth 12.0F29 (Hall 12, API Zone), where the company will present its end-to-end CRDMO services supporting every stage of drug development, from discovery, clinical development to large-scale commercial supply.
Strong Team Presence
As part of its global engagement strategy, CPC Scientific will bring together leadership, business development, and scientific expertise to CPHI, including:
-
Dr. Shawn Lee – Founder & CEO
-
Theresa Cheng – President
-
Tim Nieters – Senior Vice President, Strategic Portfolio
-
Joseph Denby – Senior Business Development Manager
-
Clàudia Badia i Lopez – Business Development Manager
-
James Gao – International Business Manager
The team will connect with existing and prospective partners to reinforce collaborations, explore new opportunities, and demonstrate the company’s enhanced capabilities and expanded capacity.
To book a meeting, email sales@cpcscientific.com or visit http://cpcscientific.com/event/cphi-frankfurt/.
Well-Positioned for Growth
CPC Scientific has adopted a “going with the compound” strategy, aligning capacity with customer demand and industry trends. Many projects in the pipeline are expected to enter commercial production in the next three to five years, driven by:
- Anticipated commercialization of multiple peptide programs
- Rapid global demand for peptide drugs, especially GLP-1 and obesity products
- Rising opportunities in generics as key patents expire across major markets
CRDMO Strengths
CPC Scientific delivers industry-leading CRDMO services with consistent advantages in quality, efficiency, and scalability:
- Comprehensive Capabilities: We provide complete lifecycle support, from discovery through preclinical research, Phase I–III clinical development, to commercial manufacturing. Our integrated model minimizes hand-offs and risk while ensuring seamless execution.
- Regulatory Excellence: Backed by nearly 25 years of expertise and a >99.95% new-molecule synthesis success rate. CPC Scientific has successfully passed 5 FDA on-site GMP inspections and 3 additional inspections by the EMA, MFDS, and TGA. In the past five years alone, the company has also completed 9 NMPA on-site or registration inspections. Certified to ISO 9001 and ISO 13485 standards.
- Scale and Innovation: Cutting-edge peptide production technologies and metric-ton scale GMP API capacity deliver unmatched efficiency and competitive scalability, with annual peptide API production of over 1,000 kg.
- Trusted Worldwide: Proven track record of strong, long-term partnerships with leading pharmaceutical and biotech companies across 50+ countries, supporting both NCEs and generic peptide development.
- GLP-1 Expertise: A recognized leader in oral and injectable GLP-1 and obesity programs, one of the most dynamic and fastest-growing segments of the global peptide drug market.
